article

1. Biological aging in multiple sclerosis..  Multiple sclerosis (Houndmills, Basingstoke, England).  29:1701-1708. 2023
2. Predictors of Disease Activity and Worsening in Relapsing-Remitting Multiple Sclerosis..  Neurology. Clinical practice.  12:e58-e65. 2022
3. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis..  Multiple sclerosis and related disorders.  -. 2022
4. Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum..  Neurology.  97:e1334-e1342. 2021
5. Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)..  Multiple sclerosis and related disorders.  -. 2021
6. Disease-modifying therapy prescription patterns in people with multiple sclerosis by age..  Therapeutic advances in neurological disorders.  -. 2021
7. Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study..  Multiple sclerosis and related disorders.  -. 2021
8. Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials..  Therapeutic advances in neurological disorders.  -. 2020
9. Immunological Aspects of Approved MS Therapeutics..  Frontiers in immunology.  -. 2019
10. Clinical trials in multiple sclerosis: potential future trial designs..  Therapeutic advances in neurological disorders.  -. 2019
11. Evolution of clinical trials in multiple sclerosis..  Therapeutic advances in neurological disorders.  -. 2019
12. Clinical trials in multiple sclerosis: milestones..  Therapeutic advances in neurological disorders.  -. 2018
13. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature..  Journal of medical case reports.  12:-. 2018
14. Distribution of cardiac output to the brain across the adult lifespan..  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.  37:2848-2856. 2016
15. Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature..  Therapeutic advances in neurological disorders.  9:211-5. 2015
16. Ubiquitin-Synaptobrevin Fusion Protein Causes Degeneration of Presynaptic Motor Terminals in Mice..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  35:11514-31. 2015